# A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

> **NCT03283085** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 557 (actual)

## Conditions studied

- Crohn's Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** 25 mg Ontamalimab
- **DRUG:** 75 mg Ontamalimab

## Key facts

- **NCT ID:** NCT03283085
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283085, "A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03283085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*